E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Parkinson's Disease |
Enfermedad de Parkinson |
|
E.1.1.1 | Medical condition in easily understood language |
Parkinson's disease |
Enfermedad de Parkinson |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. Security: control thorough laboratory tests, vital signs including blood pressure and heart rate, and physical examination findings including electrocardiogram.
2. Efficacy: assessed thorough analysis of Parkinson?s Disease-Cognitive Rating Scale change from baseline to 24 weeks after treatment with candesartan, compared to placebo. |
1. Seguridad: Evaluar la seguridad del candesartán a bajas dosis en pacientes con deterioro cognitivo leve asociado a enfermedad de Parkinson (EP-DCL), a través de la medición de las cifras de tensión arterial, frecuencia cardíaca y peso, mediante la realización periódica de analíticas y electrocardiogramas, y mediante la administración de la escala Unified Parkinson?s Disease Rating Scale (UPDRS) III, comparado con placebo.
2. Eficacia: Evaluar el potencial efecto neuroprotector del candesartán en pacientes con EP-DCL, mediante el análisis del cambio en la puntuación de la escala Parkinson?s Disease-Cognitive Rating Scale (PD-CRS), en un período de 6 meses, comparado con placebo. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are analysis of changes in serum biomarkers of neuroinflammation as well as an assessment of the effect of candesartan in executive function, functional, mood and motor scales compared to placebo |
- Evaluar el potencial efecto neuroprotector del candesartán en las funciones ejecutivas de los pacientes con EP-DCL, mediante el análisis del cambio en la puntuación de la escala Behavioural Assessment of Dysexecutive Function Scale (BADS-RS, BADS-KS, BADS-ZM y BADS-6E) y el test Tower of London (ToL), en un período de 6 meses, comparado con placebo.
- Evaluar el potencial efecto del candesartán sobre la capacidad funcional de los pacientes con EP-DCL mediante el análisis del cambio en la puntuación de las escalas Parkinson?s Disease-Cognitive Functional Rating Scale (PD-CFRS), Schwab & England scale (S&E) y The 39-item Parkinson's Disease Questionnaire (PDQ-39).
- Controlar posibles cambios de puntuación en ansiedad, depresión y apatía mediante las escalas Hospital Anxiety and Depression Scale (HADS) y Starkstein Apathy Scale (AS).
- Evaluar el efecto del candesartán sobre biomarcadores sanguíneos de neuroinflamación (Ac anti AT1R y AGEs). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
a. Patient able to understand, sign, and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures. b. Outpatients of both genders in ages between 40 and 80 years. c. Patients diagnosed of Parkinson?s disease (Movement Disorder Society PD Criteria) d. Patients with a Hoehn and Yahr stage I-III e. Patients diagnosed of mild cognitive impairment associated to Parkinson?s Disease (PD-MCI criteria based on Movement Disorder Society task force guidelines). f. Patients with a Montreal Cognitive Assessment (MoCA) rating scale score 20-25 inclusive. g. Patients diagnosed of Parkinson?s disease with stable dopaminergic treatment in the last 4 weeks. h. Patient able and willing to comply with study procedures as per protocol. i. Computerized tomography (CT) or magnetic resonance imaging (MRI) in the last 18 months compatible with the diagnosis of Parkinson?s disease. |
a. Paciente capaz de entender, firmar y fechar el consentimiento informado escrito en la visita basal, de forma previa a la aleatorización. b. Pacientes ambulatorios de ambos géneros entre 40 y 80 años. c. Pacientes diagnosticados de enfermedad de Parkinson (Movement Disorder Society PD Criteria) d. Pacientes con estadio Hoehn y Yahr entre I-III. e. Pacientes diagnosticados de deterioro cognitivo leve asociado a enfermedad de Parkinson (PD-MCI criteria basados en la Movement Disorder Society task force guidelines). f. Pacientes con una puntuación en la escala de Evaluación Cognitiva de Montreal (MoCA) entre 20 y 25, ambos inclusive. g. Pacientes diagnosticados de enfermedad de Parkinson con tratamiento dopaminérgico estable en las últimas 4 semanas. h. Paciente capaz y dispuesto a cumplir las visitas del estudio tal y como se detallan en el protocolo. i. Tomografía computerizada (TC) o resonancia magnética (RM) compatible con el diagnóstico de enfermedad de Parkinson realizada en los últimos 18 meses. |
|
E.4 | Principal exclusion criteria |
a. Illiterate patient b. Marked visual impairing or hearing loss. c. History of cardiac, hematologic, hepatic, renal, pancreatic, metabolic, respiratory, gastrointestinal, endocrinologic, or neurologic system or a tumor that is clinically significant for their participation in the study. d. Presence of significant motor complications (moderate or severe wearing off defined as score >1 on item 42 of UPDRS part IV) or disabling dyskinesia (defined as score ? 1 on item 36 of UPDRS part IV). e. History of DBS surgery. f. Patient with a diagnosis of PD Dementia (probable, possible) according to the Clinical Diagnostic Criteria for Dementia Associated with PD. g. Patients with active psychosis or major hallucinations, severe depression or delirium. h. Patients with symptomatic hypotension, hypovolemia or contraindications for taking antihypertensive medications. i. Patients whose renal function depends on Renin Angiotensin System: - Patients with cardiac failure class III or IV of the NYHA classification. - Patients with unilateral or bilateral renal artery stenosis. j. Patients taking angiotensine-receptor blockers, angiotensin-converting enzyme inhibitors or potassium-sparing diuretics. k. Patients previously treated with candesartan. l. Patients with hereditary galactose intolerance, glucose or galactose malabsortion m. Patients taking lithium. n. Patients taking acetilcholinesterase inhibitors, anticholinergic medication or dopamine receptor blockers. o. Patients who were on experimental treatments in the last 2 months previous to selection period. p. Patients presenting with one of the following conditions: - Life expectancy < 6 months - Any severe and/or uncontrolled medical condition q. Patients with history of poor compliance or history of drug/alcohol abuse, or current drug/alcohol abuse that might interfere with the ability to comply with the study protocol or give informed consent r. Pregnancy or breastfeeding. s. Patients with evidence of severe vascular pathology or white matter diffuse involvement in CT or MRI. |
a. Paciente analfabeto. b. Paciente con afectación severa de la visión o audición. c. Historia de enfermedad cardíaca, hematológica, hepática, renal, pancreática, metabólica, respiratoria, gastrointestinal, endocrinológica, neurológica o neoplásica, que sea clínicamente relevante para su participación en el estudio. d. Presencia de complicaciones motoras relevantes (wearing off moderado o severo definido como una puntuación >1 del item 42 de la parte IV del UPDRS) o discinesias incapacitantes (definidas como una puntuación >1 en el item 36 de la parte IV del UPDRS). e. Historia de cirugía de estimulación cerebral profunda. f. Pacientes con diagnóstico de demencia (posible o probable) asociada a la enfermedad de Parkinson, según el Clinical Diagnostic Criteria for Dementia Associated with PD. g. Pacientes con psicosis activa o alucinaciones mayores, depresión severa o delirio. h. Pacientes con hipotensión sintomática, hipovolemia o contraindicaciones para la toma de medicación antihipertensiva. i. Pacientes cuya función renal dependa del sistema renina-angiotensina: o Pacientes con insuficiencia cardíaca clase III o IV de la clasificación NYHA. o Pacientes con estenosis renal uni o bilateral conocida. j. Pacientes que estén tomando ARAs, IECAs o diuréticos ahorradores de potasio. k. Pacientes previamente tratados con candesartán. l. Pacientes con intolerancia hereditaria a la galactosa, glucosa o malabsorción de galactosa. m. Pacientes que estén tomando litio. n. Pacientes que estén tomando inhibidores de la acetilcolinesterasa, medicación anticolinérgica o antagonistas de los receptores de dopamina. o. Pacientes que estuvieran bajo tratamiento experimental en los 2 meses previos al período de selección. p. Pacientes con cualquiera de las siguientes situaciones: o Esperanza de vida inferior a 6 meses. o Cualquier condición médica severa o no controlada. q. Pacientes con historia de bajo cumplimiento terapéutico o abuso de drogas/alcohol que pueda interferir con la capacidad del paciente para cumplir el protocolo del estudio o dar el consentimiento informado. r. Embarazo o lactancia. s. Pacientes con evidencia de patología vascular severa o alteración relevante de sustancia blanca por TC o RM. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Absolute change in Parkinson?s disease-Cognitive Rating Scale score |
Cambio absoluto en la Parkinson?s Disease-Cognitive Rating Scale (PD-CRS) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Absolute change in executive function scales: Behavioral Assessment of Dysexecutive Syndrome (BADS) and Tower of London (ToL), from baseline to week 24.
- Absolute change in functional scales: Parkinson?s disease-Cognitive Functional Rating Scale, Schwab & England and 39-item Parkinson's Disease Questionnaire scores, from baseline to week 24.
- Absolute change in mood scales: Starkstein Apathy Scale (AS) score and Hospital Anxiety and Depression Scale (HADS) score, from baseline to week 24.
- Absolute change in motor state assessed by Unified Parkinson?s disease Rating Scale-part III, from baseline to week 24.
- Absolute change in serum biomarkers: advanced glycosylation end products and AT1R antibodies, from baseline to week 24. |
Cambio en las siguientes escalas: - Behavioral Assessment of Dysexecutive Syndrome (BADS) y Tower of London (ToL). - Parkinson?s disease-Cognitive Functional Rating Scale, Schwab & England y 39-item Parkinson's - Disease Questionnaire scores. Starkstein Apathy Scale (AS) score and Hospital Anxiety and Depression Scale (HADS) score. - Unified Parkinson?s disease Rating Scale-part III - Cambio en los biomarcadores séricos: productos finales de glicosilación avanzada, y anticuerpos AT1R |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Ultima visita del último sujeto |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 20 |
E.8.9.1 | In the Member State concerned days | |